Glycinorm OD 30mg Tablet MR contains Gliclazide 30mg, a sulfonylurea class oral hypoglycemic agent indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with non-insulin-dependent diabetes. The modified-release (MR) formulation ensures a sustained and gradual release of Gliclazide, providing prolonged blood glucose regulation and reducing the risk of hypoglycemia compared to immediate-release formulations. Glycinorm OD is typically prescribed as part of a comprehensive diabetes management plan, including diet, exercise, and weight control. It is particularly useful in patients inadequately controlled by diet alone or in combination with other antidiabetic agents. Dosage should be individualized based on patient response and glycemic targets, with regular monitoring of blood glucose and HbA1c levels to assess efficacy and safety. Caution is advised in patients with renal or hepatic impairment, and it is contraindicated in type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Common adverse effects include hypoglycemia, gastrointestinal disturbances, and allergic reactions. Patient education on recognizing hypoglycemia symptoms and adherence to prescribed therapy is essential for optimal outcomes.